Pharmacology & Therapeutics 1991: Vol 49 Index

9 Pages·1991·1.8 MB·English

AUTHOR INDEX
Kalix, P. 397
Lee, I.-S. 345
Lulich, K.M. 295
MacDonald, P.S. 323
Mebs, D. 223
Muggia, F.M. 61
O’Dwyer, P. J. 371
Oritz de Montellano, P.R. 95
Ownby, C. L. 223
Ozols, R. F. 19
Daher, G.C. 189
Diasio, R. B. 189
Dusting, G. J. 323
Parker, W. B. 381
Paterson, J. W. 295
Edwards, G. 237 Perez, R. P. 19
Putney, J. W. Jr. 427
Fairbrother, 1. S. 281
R4édl,S. 1
Feely, J. 71
Rahmsdorf, H. J. 157
Ross, V. 357
Roth, R. A. 143
Sanna, E. 121
Serra,M. 121
Speyer, J.L. 61
Suzuki, T. 357
Vinegar, A. 143
Webb, G. 357
Weston, A.H. 237
Winquist, R. J. 417
Johnston, P. 357 Wintersberger, U. 259
SUBJECT INDEX
A-62824 6 Amifloxacin 4
A-65485 9 Amiloride, ANF interaction 418
Acetylcholine receptor-gated K-channel 239 Amines, accumulation in lung 146
Adenosine-3’ ,5'-monophosphate Aminopyrine breath test 75
gated K-channel 240 Amiodarone
vascular effect of prostacyclin 332 accumulation in lung 146
Ca?+-Adenosine triphosphatase, in muscle, effect inhibition of drug metabolism 85, 86
of myotoxin a 231 Amphetamine
Adenosine triphosphate-dependent comparison with khat alkaloids 397, 401, 402
K-channels 240, 242 induced dopamine release 282, 283
Adenylate cyclase Analgesic drugs, inhibition of drug metabolism 86
activation by prostacyclin 332 Angina pectoris, effect of potassium channel
airway smooth muscle relaxation 297 openers 249
Adenylate cyclase/B-adrenoceptor system, Anthracycline, selective alteration of activity by
asthma 302 ‘ ICRF-187 61-69
a-Adrenoceptors Antiarrhythmics, inhibition of drug
asthma 308 metabolism 85
in vitro studies of airways 309 Antibacterial agents, DNA gyrase inhibitors 1-17
mechanisms of action 307 Antifolate drugs
subclassification 306 malaria chemotherapy 45
a-Adrenoceptor agonists 306 malaria parasite resistance 47
effect on airway smooth muscle in vitro 309 Anti-inflammatory drugs, inhibition of drug
effect on asthma 308 metabolism 86
a-Adrenoceptor antagonists 306 Antipyrine, assessment of enzyme induction and
effect on airway smooth muscle in vitro 309 inhibition 74
effect on asthma 308 Antiviral drugs, retroviral RNases H as
a,-Adrenoceptor-gated K-channel 239 targets 266 -
B-Adrenoceptors Anxiety, GABAergic transmission 122
aging and function 330 Anxiogenic drugs
airway smooth muscle 299 Cl- flux 125, 128
density and distribution in lung 298 dopaminergic transmission 135
molecular nature 297 GABAergic transmission 124, 124
respiratory virus interaction 301 TBPS binding 126, 130
“ subclassification 296, 299 Anxiolytic drugs
B-Adrenoceptor agonists Cl- flux 125, 128
action on airway smooth muscle 299 dopaminergic transmission 135
clinical action in lung 304 GABAergic transmission 122, 124
role in inflammation 306 TBPS binding 126, 130
sites of action 305 AP-1
tolerance 306 binding to TREs 168
B-Adrenoceptor kinase 297 role in tumor promotion 175
Adriamycin, resistance in ovarian cancer cells 19 AP-2 171
Aging, pulmonary B-adrenoceptor function 300 Aphidicolin, effect on drug resistance 24
Airway epithelium, B-adrenoceptor function 301 Aplysiatoxin 158
Airway smooth muscle Appetite suppressant, cathine 405
a-adrenoceptors 306 1-B-D-Arabinofuranosylcytosine
B-adrenoceptors 299 biochemical modulation
clinical action of B-agonists 304 deaminase inhibitors 36
B-Alanine synthase, pyrimidine catabolism 193 growth factors 38
Alkylating agents, resistant ovarian cancer inhibitors of de novo pyrimidine
cells 19 biosynthesis 32
4-Alkyl-1,4-dihydropyridines, reaction with protective agents 38
heme 104 transport blockers 37
Alkylhydrazines, reaction with heme 103, 106 chemistry 204
Allergens, induced reduction in B-adrenergic cytotoxicity 30
function on asthmatic lymphocytes 302 metabolic sites of action 210
Allopurinol, effect on drug metabolism 87 metabolism 30, 206
Alpidem transport 31
effect on GABA binding in brain 125 uptake into cells 205
effect on TBPS binding in brain 126 9-B-p-Arabinofuranosyl-2-fluoroadenine,
Alveolar hypoxia 151 modulation of ara-C 35
SUBJECT INDEX
Brain microdialysis, dopamine release and
phoestrer ibnducoed lrele ase 172 metabolism in vivo 281-293
potassium channel opening properties 251 BrCCl,, reaction with heme 97
Breast cancer, PALA/S-fluorouracil treatment 376
Artelinic acid, metabolism 351
Artemether 347
metabolism 350 Bronchial hyperactivity, B-adrenoceptor
Artemisinin 345 agonisi ts 306
metabolism 349 Bronchoconstriction, effect of B-adrenoceptor
Artesunic acid, metabolism 351 agonists 299
Artheether 346 Bronchodilation, effect of B-adrenoceptor
metabolism 350 agonists 304
Arylhydrazines, reaction with heme 106 Bryostatin-1, modulation of ara-C 39
Aspartate carbamy]l transferase, inhibition by Buthionine sulfoximine, effect on
PALA 371, 373 chemoresistance 21
Asthma, role of adrenoceptors 296, 302, 308 t-Butylbicyclophosphorothionate, binding in brain
effect of a-agonists 308 effect of anxiolytic, anxiogenic drugs 126
effect of B-agonists 299, 304 effect of stress 130
effect of a-antagonists 308
exercise-induced 309
respiratory virus — B-adrenoceptor
interaction 301 Cadeguomycin, modulation of ara-C 35
AT-4140 8 Calcitonin gene-related peptide, vasorelaxant
Atherosclerosis, prostacyclin production 333 properties 251
Atrial natriuretic factor 417 Calcium
receptors 420 effect of potassium channel openers on
vascular effects in vitro 418 intracellular stores 246
vascular effects in vivo 421 receptor-regulated entry 427-434
Atriopeptin I 420, 421 capacitative model 429, 431
Autoreceptor, control of dopamine release 290 Ins(1,4,5)P,; 428, 432
Aversion, cathinone 406 route 430
idine Calcium antagonists, inhibition of drug
chemistry 211 metabolism 85
metabolic sites of action 213 Captopril 335
metabolism 211 Carbamazepine
uptake into cells 211 erythromycin interaction 86
Azide, reaction with heme 103 induction of drug metabolizing enzymes 79
verapamil interaction 85
lines
effect on Cl- flux 126
Behavioural effects of khat alkaloids 404 effect on GABA, /benzodiazepine receptor
Bendrofluazide 335 function 132
Benzodiazepine receptor ligands 124 effect on GABA binding in brain 124
Benzodi effect on GABA transmission 123
anxiolytic effect and activation of GABA, effect on TBPS binding in brain 127
receptor 122 Cardiovascular drugs, inhibition of drug
effect on Cl- flux 126 metabolism 85
effect on dopaminergic transmission 135 Cardiovascular system
effect on GABA binding in brain 124 effects of khat 399, 402
effect on TBPS binding in brain 126 effect of prostacyclin 329
tolerance 132 Cathine 401
Benzopyrans, K-channel openers 240 behavioural and CNS effects 404
Benzo(a)pyrene, metabolic clearance 147 cellular effects 408
Benzo(a)pyrene hydroxylase, in lung 146 somatic effects 402
Bilirubin, in plasma, indicator of enzyme Cathinone 402
induction 77 behavioural and CNS effects 404
Biliverdin formation 110 cellular effects 407
6-Blockers, inhibition of drug metabolism 85 somatic effects 403
Blood flow Caudoxin 225
coronary, effect of ANF 422 Cerebral vasospasm
kidney, effect of ANF 422 effect of potassium channel openers 249
effect of prostacyclin 329 effect of prostacyclin 336
splanchnic, effect of ANF 422 Chemotherapeutic agents, inhibition of drug
Blood pressure, effect of potassium channel metabolism 86
Chemotherapy, resistance to alkylating agents and
cisplatin 19
prostacyclin biosynthesis 325 Chlorgyline, effect on dopamine release 288
in-EDRF interaction 332 Chlorobiocin 2
BMY-40062 5,9 , inhibition of drug
Bothropstoxin 234 metabolism 87
SUBJECT INDEX
5’-Deoxy-5-fluorouridine 204
Deoxyguanosine, modulation of ara-C a
prostaglandin :
Cimetidine, inhibition of drug metabolism 84
Cinoxacin 3, 4,6 prostacyclin production
Ciprofloxacin 4, 5,7 2,2-Dialkyl-1,2-dihydroquinolines, reaction with
Cisplatin, resiins ovtariaan ncanccere ce lls 19 heme 104
CL 218872 Diazoxide 242, 243
effect on GABA binding in brain 124 antihypertensive effects 248
effect on TBPS binding in brain 126 interaction with K-channels 244
Cl~ flux Diet, effect on drug metabolism 80
anxiolytic, anxiogenic drugs 125 Diethylpropion 410
stress 128 Difloxacin 5
Clonidine, effect on airway function 306, 312 Dihydroalprenolol, binding to pulmonary
Collagenase TRE 164 B-adrenoceptors 298, 302
Colorectal cancer, PALA/S5-fluorouracil Dihydroartemisinin 347, 353
therapy 375 Dihydroer, » binding iin lung 309
Coronary blood flow, effect of ANF 422 Dihydrofolate reductase, in Plasmodium 47
Corticosteroids, interaction with enzyme inducing Dihydrofolate reductase mRNA, effect of
agents 81 5-fluorouracil 384
Coumarin antibiotics 1 Dihydrofolate reductase — thymidylate synthetase
structure-activity ‘raat 2 gene
Coumermycin Al chromosomal mapping 50
Crigler—Najjar ae type II 80 cloning 48
Cromakalim drug resistance in malaria parasites 45-59
effect on blood pressure 248 point mutations in DHFR-encoding domain 51
interaction with K-channels 242, 244 Dihydropyrimidinase, pyrimidine catabolism 193
in vitro pharmacodynamics 245 Dihydropyrimidine dehydrogenase, pyrimidine
in vivo pharmacodynamics 246 catabolism 192
Crotamine 224 Diltiazem, inhibition of drug metabolism 85
effect on skeletal muscle 231 Dipyridamole, modulation of ara-C 37
Crotoxin 225 Disulfiram, effect on drug metabolism 87
effect on skeletal muscle 232 DNA
Cruoralbin 96 effect of ara-C on biosynthesis and repair 210
Cyanide, reaction with heme 96 5-fluorouracil action on 387
Cyanoguanidines, potassium channel openers 241 5-fluorouracil incorporation 203, 388
125]-Cyanopindolol, binding to pulmonary retroviral, functions of RNasesH 264
B-adrenoceptors 3-2 RNases H 272
Cyclo-oxygenase, hypertension 334 role in chemoresistance 22
Cyclopropanone hydrate, reaction with heme 101 TPA responsive elements 164
Cytidine deaminase DNA gyrase inhibitors, structure—activity
ara-C metabolism 31, 206 relationships 1-17
azacytidine metabolism 212 DNA primase, 5-fluorouracil interaction 387
fluoropyrimidine metabolism 382 DOPAC, neuronal source 288
inhibitors and modulation of ara-C 36
Cytochrome P450 actions of 290
N-alkyl adducts 107 autoreceptors 290
covalent binding of prosthetic heme group 109 carrier-dependent release 283
enzyme induction and inhibition 73 exocytotic release 281
isoenzymes in lung 144 experimental model of release mechanisms 286
Cytochrome P450 monooxygenases, in lung 144 intraterminal stores 285
Cytokines, stimulation of prostacyclin effect of MAO inhibitors 288
production 327 receptors 289, 290, 291
Cytoprotection, prostacyclin 331 releasing agents 282
Dopaminergic transmission, mesocortical
pathway 134
anatomical aspects 134
Danfloxacin 9 biochemical indexes 134
3-Deazauridine, modulation of ara-C 32 role of GABAergic transmission in control of
Defibrotide, effect on prostacyclin release 328 neurons 135
Deoxyadenosine, modulation of ara-C 34 stress and function of 135
Deoxycytidine, ara-C interaction 38 Doxorubicin, cardiotoxicity, effect of ICRF-
Deoxycytidine kinase, ara-C anabolism 208 187
Deoxycytidylate deaminase Drug metabolism, enzyme induction and
ara-C catabolism 31, 207 inhibition 71-94
inhibitors and modulation of ara-C 36 Drug resistance
Deoxycytidylate kinase malaria parasites 45-59
ara-C anabolism 209 ovarian cancer cells 19
azacytidine metabolism 213 Dyad symmetry elements binding complex 170
SUBJECT INDEX
Eicosanoids, biosynthesis and metabolism 324 5-Fluorouracil
Eicosapentaenoic acid, effect on prostacyclin chemistry 190
activity 328 DNA-directed actions 387
EMD 52692 241 metabolic site of action 202
in vivo pharmacodynamics 247 metabolism 191, 381
Emotional states, cortical GABAergic and modulation of ara-C 36
dopaminergic transmission 121 PALA interaction 374
Endothelium-derived hyperpolarizing factor, RNA and DNA incorporation 202
vascular relaxation 250 RNA-directed action 384
Endothelium-derived relaxant factor 249, 250 uptake into cells 190
effect of fish oils on generation of 329 Folate, metabolism in malaria parasites 46
effect on prostacyclin biosynthesis 328 Food intake, effect of khat alkaloids 405
prostacyclin interaction 332 Free radicals, modification of prosthetic heme
Endothelium, vascular groups 95-120
ANF receptors 420 Ftorafur 204
antithrombotic function 332
prostacyclin production 325
Enoxacin 4,7
Enzyme induction 71, 73
assessment 74 GABA, binding in brain
implications 80 effect of anxiolytic, anxiogenic drugs 124
inducers 77 effect of stress 128
induction of extrahepatic drug metabolizing GABA,/benzodiazepine ligands, anxiety 122
enzymes GABA, /benzodiazepine receptor
Enzyme inhibition 83 anxiolytic, anxiogenic drugs and Cl- flux 125
anti-inflammatory and analgesic drugs 86 anxiolytic, anxiogenic drugs and GABA
assessment 74 binding 124
cardiovascular drugs 85 anxiolytic, anxiogenic drugs and TBPS
chemotherapeutic agents 86 binding 126
neuroleptics 87 chronic anxiogenic B-carbolines and function
oral contraceptives 87 of
ulcer healing drugs 84 stress and function 121, 128
Epilepsy, treatment with enzyme inducers 80 GABAergic transmission 122
Epithelium, airway, B-adrenoceptor function 301 anxiolytic, anxiogenic drugs 124
Erythromycin, inhibition of drug metabolism 86 GABA, /benzodiazepine receptor function and
Escherichia coli B-carbolines 132
reverse transcriptases 269 GABA, /benzodiazepine receptor function and
RNases H 267 stress 128
Ethanol GABA, /benzodiazepine receptor ligands and
induction of drug metabolizing enzymes 79 anxiety 122
effect on TBPS binding in brain 128 role in control of activity of mesocortical
Ethylhydrazine, reaction with heme 103 dopaminergic neurons 135
Exercise-induced asthma 309 Gene expression, regulation by tumor
promoters 157-188
Gilbert’s syndrome 80
Fear, cortical GABAergic and dopaminergic Glibenclamide 244, 245
transmission 121 p-Glucaric acid, urinary, indicator of enzyme
Fenoterol, bronchodilator effect 300, 304 induction 76
FG 7142 Glucocorticoids, interference with transcription
inhibition of GABAergic system in CNS 133 factor activity 175
proconflict response 123 Glucose, effect of enzyme inducers on
effect on TBPS binding in brain 132 metabolism 81
Fish oils, effect on prostacyclin activity 328 y-Glutamyltransferase, indicator of enzyme
Flavin monooxygenases in lung 145 induction 76
Fleroxacin 4 Glutathione
Flumequine 3, 4 in heart, effect of doxorubicin 64
5-Fluorodeoxycytidine 382 role in resistance, to alkylating agents and
5-Fluoro-2'-deoxyuridine platinum compounds 21
metabolic site of action 202 Glutathione S-transferases
metabolism 194 genetic heterogeneity 357
uptake into cells 191 alpha class 359
5-Fluoro-2’-deoxyuridine monophosphate 200 mu class 361
5,10-methylene tetrahydrofolate and TMP piclass 365
synthetase interaction 387 role in drug resistance 22
Fluoropyrimidines G proteins
DNA-directed actions 387 a-adrenoceptor action 307
metabolism 381, 383 B-adrenoceptor action 297
effect on PALA antitumour activity 375 Green hemoglobins 96
RNA-directed actions 384 Growth factors, modulation of ara-C 38
structure 382 Guanosine-3’ ,5'-monophosphate, vascular, effect of
Fluoroquinolones 5, 7 ANF 418
x SUBJECT INDEX
Halocarbons, reaction with heme 97, 108 peripheral actions 399
Heart psychosis 398
effect of ANF on blood flow 422 somatic effects of alkaloids 402
effect of ICRF-187 on anthracycline toxicity 62 Kidney, ANF-induced vasodilation 421, 422
prostacyclin biosynthesis 326
prostacyclin effects 329
Heme oxygenase 110 Lemakalin 240
Heme prosthetic groups, modification 95 Leukemia, biochemical modulation of ara-C 29
covalent protein binding 109 Ligand-gated K-channels 239
hydrogen abstraction 104 Lomefloxacin 8
intrinsic radical reactivity 112 Lung
iron and pyrrole nitrogen addition 104 accumulation of xenobiotic agents 145
meso addition 100 a-adrenoceptors 308, 309
ring oxidation and degradation 110 B-adrenoceptors 298
vinyl group addition 96 altered physiology and metabolic clearance of
Hepatitis B viruses, reverse transcriptases 264 xenobiotic agents 151
High density lipoprotein, effect of enzyme cytochrome P450 monooxygenases 144
inducers 82 determinants of metabolic clearance of
H2TF1 171 xenobiotic agents 145
Human immunodeficiency virus, reverse flavin monooxygenases 145
transcriptase 263, 267 physiologically-based pharmacokinetic modeling:
Hybrid arrest translation, RNase H 273 benzo(a)pyrene clearance 147
Hydrogen abstraction, modification of heme LY 222675 241
prosthetic groups 104
Hydrogen peroxide, reaction with heme 96
Hydrogen sulfide, reaction with heme 99 Malaria
68-Hydroxycortisol, urinary excretion, indicator of antifolate drugs in chemotherapy 45
enzyme induction 76 metabolism of sesquiterpene lactones 345-355
Hydroxyurea, modulation of ara-C 34 parasite resistance to antifolates 47, 52
Hypertension Melphalan, resistance in ovarian cancer cells 19
effect of potassium channel openers 248 Meso addition, modification of heme prosthetic
prostacyclin production 334 groups 101
Hyperthermia, khat-induced 400, 404 Mesocortical dopaminergic pathway 134
Hypotension, ANF-induced 421 GABA transmission in control of neurons 135
stress and function of 135
Metallothioneins, role in cisplatin resistance 22
ICRF-187, selective alteration of anthracycline Metallothionein IIA promoter 166
activity 61-69 Methotrexate, modulation of ara-C 35
Iloprost 250 Methoxamine, effect on asthma 308, 309
cytoprotective actions 331 5,10-Methylene tetrahydrofolate, FA UMP and
Imipramine, accumulation in lung 146 TMP synthetase interaction 387
Inflammation, B-adrenoceptor agonists 306 a-Methyl-p-tyrosine, effect on dopamine
Influenza viruses, B-adrenoceptor interaction 301 release 285
Inositol trisphosphate Metmyoglobin, vinyl modification 97
calcium entry 428, 431 Mezerin 158
gated K-channel 240 Microcirculation, effect of prostacyclin 330
Ion exchange, effect of phorbol esters 173 Miloxacin 3,4
Ion-gated K-channels 239 Minoxidil sulfate 242, 243
Ion transport, effect of myotoxic components of antihypertensive effect 248
snake venom 231 Mojave toxin 225
Irloxacin 8 Molsidomine 333
Iron, modification of heme prosthetic groups 104, Monoamine oxidase inhibitors
114 effect on dopamine release 288
Ischaemic heart disease, effect of potassium effect on drug metabolism 87
channel openers 249 Murine leukemia virus, reverse transcriptase 261
Ischaemic tissue damage, effect of Muscle, toxic components from snake
prostacyclin 336 venom 223, 226
Isoniazid Myocardial ischaemia, effect of potassium channel
inhibition of drug metabolism 86 openers 249
effect of proconflict effect of B-carbolines 123 Myoglobin
stress and convulsant activity 131 covalent binding of prosthetic heme group 109
effect on TBPS binding in brain 127 nitrite-heme reaction
Isoprenaline, bronchodilator action 304 Myotoxic components of snake venom
peptides 224, 228
phospholipases A2 225, 232
KB-5246 6 Myotoxin a 224
Khat 397 effect on skeletal muscle 228
active constituents 401
behavioural effects 404
cellular effects 407 NAD-441A 11
CNS stimulation 398, 404 Nalidixic acid 3
SUBJECT INDEX
Neuroleptics, inhibition of drug metabolism 87 activation of transcription factors 168
Neutrophils, effect of prostacyclin 330 induced signal transduction 172
NF,B 171, 172 pase A2
Nicorandil 241, 243 effect on pulmonary B-adrenoceptor
hemodynamic effects 247, 249 function 303
Nicotinyl alcohol, effect on prostacyclin snake venoms, myotoxicity 225, 232
release 328 Phospholipidosis, pulmonary 146
Niguldipine 242, 243 Phosphonacetyl-L-aspartate
Nitric oxide, prostacyclin interaction 332 biochemical modulation of 5-fluorcuracil 374
Nitrite, reaction with heme 97 clinical studies 374
Nitroglycerin mechanism of action 371
prostacyclin interaction 333, 335 modulation of ara-C 32
effect on prostacyclin release 328 pharmacodynamics 373
Nitromethane, reaction with heme 101 pharmacokinetics 372
Nitroprusside preclinical antitumor activity 372
prostacyclin interaction 333, 335 Physiologically-based pharmacokinetic modeling,
effect on prostacyclin release 328 metabolic clearance of benzo(a)pyrene 147
Nomifensine, effect on dopamine release 284, 285 Pinacidil 241
Norfloxacin 4,7 antihypertensive effects 248
Notechis [I-5 225 interaction with K-channels 244
Notexin 225 in vivo pharmacokinetics 246
effect on skeletal muscle 232, 234 Pipemidic acid 3, 4
Novobiocin 2 Piromidic acid 3, 4
Nucleoside diphosphate kinase Plasminogen activators, effect on prostacyclin
ara-C metabolism 210 release 328
azacytidine metabolism 213 Plasmodium chabaudi, experimentally induced
fluoropyrimidine metabolism 198 mutations 55
Nucleoside monophosphate kinase, Plasmodium falciparum
fluoropyrimidine metabolism 198 dihydrofolate reductase activity 47
Nutrition, effect on drug metabolism 80 dihydrofolate reductase-thymidylate synthetase
gene 45, 48
experimentally induced mutations 54
Ofloxacin 4,5, 10 resistance to antifolates 47
Olefins, reaction with heme 107 Platelet activating factor
Oligodeoxyribonucleotides effect on pulmonary B-adrenoceptors 304
antiviral activity 267 regulation of prostacyclin biosynthesis 327
directed RNA cleavage 273 Platelets
Omeprazole, inhibition of drug metabolizing prostacyclin actions 330
enzymes prostacyclin-EDRF interaction 332
Oncogenes, effect of tumor promoters 159 Platinum compounds, resistance to 19
OP-2505 and OP-41483, cytoprotective effect 331 Polymorphonuclear leukocytes, effect of
Oral contraceptives, effect on drug prostacyclin 330
metabolism 87 Polypharmacy, enzyme induction and
Orotate phosphoribosyltransferase 196 inhibition 72
Quabain, induced dopamine release 282, 284 Potassium, induced dopamine release 282
Ovarian cancer cells, resistance to alkylating Potassium channel openers
agents and cisplatin 19-27 endogenous 250
Oxolinic acid 3,4 synthetic 240
chemical structures 240
clinical uses 247
Palytoxin 158 interactions with specific K-channels 242
Parenchyma, B-adrenoceptors 298 in vitro pharmacodynamics 245
Pargyline, effect on dopamine release 288 in vivo pharmacodynamics 246
PD-124816 7 Potassium channels
Pefloxacin 4 ion-gated 239
Peripheral vascular disease, prostacyclin 336 ligand-gated 239
Phenobarbitone second-messenger/intracellular metabolite-
effect on Crigler—Najjar syndrome and Gilbert’s gated
syndrome 80 vascular tone 238
drug interactions 78, 79 voltage-gated 238
enzyme induction 73, 78 Prazosin 306
Phentolamine, effect on asthma 308 binding in lung 309
Phenylbutazone, inhibition of drug metabolism 86 effect on exercise-induced asthma 309
Phenylephrine 306 Pregnancy, prostacyclin production 335
effect on lung 308, 312 Proguanil 45, 46
Phenylhydrazine, reaction with heme 102 Propranolol, inhibition of drug metabolism 85
Phenytoin Prostacyclin
induction of drug metabolizing enzymes 78 action in cardiovascular system 329
isoniazid interaction 86 action on platelets, blood cells and
Phorbol esters cytoprotection 330
action on genes 159 activation of adenylate cyclase 332
SUBJECT INDEX
biosynthesis and metabolism 324 Rosoxacin 3, 4
clinical applications 335 Rotor’s Syndrome 361
interaction with endothelial factors and RP 49356 241
nitrovasodilator drugs 332 interaction with K-channels 243, 244
K-channel opening properties 250 RP 52891 241
production in vascular disease 333 Rufloxacin 5, 6
receptors 331
regulation of biosynthesis 326
in E2, modulation of ara-C 38 Salbutamol, bronchodilator effect 300, 302, 304
Sarcoma-leukosis virus group, reverse transcriptase
Protein, phorbol ester induced
phosphorylation 173 from 261
Protein kinase C Sarcoplasmic reticulum, effect of myotoxin a 231
receptor for tumor promoting phorbol Satellite cells, effect of myotoxic
esters 172 232
regulation of prostacyclin biosynthesis 327 SDZ PCO 400, effect on vascular tone 247
Pseudoheme Serum response factor p 67 170
Pulmonary hypertension, effect of Sesquiterpene lactone antimalarials,
prostacyclin 336 metabolism 345-355
Signal transduction, phorbol ester induced 172
Pyrazofuran, modulation of ara-C 32
Pyrazoloimidazole, modulation of ara-C 35 Simian retroviruses, reverse transcriptase
Pyrimethamine 45, 46 from 263
Skeletal muscle
Pyrimidine analogues, metabolism 189-222
Pyridimines, inhibition of synthesis by effect of ANF on circulation 423
PALA 371, 375 normal structure 226
Pyrrole nitrogen, modification of heme prosthetic snake venom induced necrosis 223, 228
groups 104 Skin tumor promoters 158
Smoking, drug interactions 79
Snake venoms 223
Quinidine, inhibition of drug metabolism 85 myotoxic peptides 224
Quinolones 1 myotoxic phospholipases A2 225
pathogenesis of myonecrosis 226
chiral 10
effect on drug metabolism 86 SO 121 241
structure-activity relationships 3 Sodium channel, effect of myotoxins 231
Sodium—potassium-chloride transport system,
effect of phorbol esters 173
Reserpine, effect on dopamine release 285 Species differences, ANF-induced
Respiratory viruses, interaction with B- vasodilation 420
adrenoceptors 301 Splanchnic circulation, effect of ANF 423
Retroviruses, RNasesH 261 Stomatitis, khat induced 400
Reverse transcriptase 259 Streptokinase, effect on prostacyclin release 328
avian, murine and simian retroviruses 261 Stress
bacterial 269 function of mesocortical dopaminergic
hepatitis B viruses 264 pathway 135
HIV 263 GABA, /benzodiazepine receptor function 128
Rhinovirus-16, B-adrenoceptor interaction 301 GABAergic transmission 122
Ribonuclease H 260 Subarachnoid hemorrhage, effect of
cellular origin 267 prostacyclin 336
biological functions 272 Sulfhemoglobin 99
E.coli 267 Sulfinpyrazine, inhibition of drug metabolism 86
Sulfite, reaction with heme 104
multicellular organisms 271
Sulfonamides, effect on drug metabolism 86
yeast 270
SV 40 promoter 166
retroviral origin 261
protein binding 170
targets for antiviral drugs 266
Sydnones, reaction with heme 107
tool in molecular biology 272
Ribonucleotide reductase, fluoropyrimidine Systemic lupus erythromatosis, prostacyclin
metabolism 199 production 335
Ribonucleotide reductase inhibitors, modulation of
ara-C 33 Taipoxin, effect on skeletal muscle 232
Rifampicin, induction of drug metabolizing Teleocidin 158
enzymes 77 Temefioxacin 8
RNA Terbutaline, bronchodilator action 304
fluorouracil incorporation 202, 384, 385 12-O-Tetradecanoylphorbol-13-acetate 158
phorbol ester induced accumulation or induced signal transduction 172
decrease 163 responsive DNA elements 164
fluorouracil incorporation 202, 384, 385 protein binding 167
phorbol ester induced accumulation or responsive genes 160-162
decrease 163 RNA accumulation or decrease 163
Ro 15-1788 123 Tetrahydrouridine 207, 212
Ro 15-4513 123 ara-C interaction 36
Ro 23-9424 11 Tetramic acid analogues 11
Ro 31-6930 241 Thapsigargin 431
SUBJECT INDEX xiii
Thioformamide derivatives, potassium channel Valproic acid, inhibition of drug metabolism 87
Openers 241 Vascular disease
Thioridazine, inhibition of drug metabolism 87 clinical applications of prostacyclin 335
Thrombotic throm i prostacyclin production 333
prostacyclin production 335 Vascular smooth muscle
Thromboxane A2, production by vascular effect of ANF 418
tissues 325 potassium channel openers 238, 245, 247, 250
Thymidine, ara-C interaction 33 Vascular tissue
Thymidine kinase 197 prostacyclin action 329
Thymidine nucleotides, metabolism 389 prostacyclin biosynthesis 325
Thymidine phosphorylase 196 Vasodilation, ANF induced 417
Thymidylate synthase, fluoropyrimidine in vitro 418
interaction 200, 387 in vivo 421
Thymus, RNases H in 271 Verapamil, inhibition of oxidative metabolism 85
Thyroid, effect of enzyme inducers on Veratrine, induced dopamine release 282, 284
metabolism 81 Verdoheme 111
TK-1000, cytoprotective effect 331 Vinyl group addition, heme 96
Tosufloxacin 8 Viral genes, effect of tumor promoters 161, 163
Trachea Virus, interaction with B-adrenoceptors 301
a-adrenoceptors 310 Vitamin D, effect of inducing agents on
B-adrenoceptors 298 metabolism 81
Transplant preservation, effect of prostacyclin 336 Voltage-gated K-channel 238
TREs 164
protein binding 167
Triacetyloleandomycin, inhibition of drug WAY-120,491 247
metabolism 86 WB4101 307
Tumor promoters, regulation of gene
expression 157-188
Tyramine, induced dopamine release 282, 285 Yeast, RNases H 270
Ulcer healing drugs, enzyme inhibition 84 ZK 93423 and ZK 91296
Uracil N-glycosylase, 5-fluorouracil toxicity 391 effect on GABA binding in brain 125
Uridine/cytidine kinase, azacytidine effect on TBPS binding in brain 126
metabolism 212 Zolpidem
Uridine kinase 195 effect on GABA binding in brain 125
Uridine phosphorylase 194 effect on TBPS binding in brain 126